Entering text into the input field will update the search result below

Powerful ICE: Monday Dec 7, 2020

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

As you know, I didn't forget you. It's just that I've been extremely busy running two companies. You are important to me so I worked out the kinks in my schedule to better help you in your stock due diligence.

As such, I'm pushing hard to share with you your Powerful IBI Community Experience (i.e., ICE). Here, I'll feature notable discussions between me and stellar IBI members.

Dr. Tran (i.e., BioSci Capital Partners)

Just a quick market recap.

Clovis Oncology (CLVS) gave up some recent gains.

Axsome Therapeutics (AXSM) is trading on an uptrend as it closed in the green today +1%.

Intra-Cellular Therapies (ITCI) follows the same trend with +1.27% gains.

Amarin Corporation (AMRN) reached beyond $5 with 1.4% gains.

ImmunoGen (IMGN) hit above $6 and ended the day today in the green.

BioCryst Pharmaceuticals (BCRX) continues to rip it with another 18% gains. It's at $7.22. This is unusual for a stock after drug approval.

NovaVax (NVAX) continues to slump, as it traded slightly down today.

Moderna (MRNA) continues to move aggressively up to $159. If you had taken some profits like banderson1, it's great to have some shares to ride further upside until we have full approval for the COVID vaccine.

It's important that you have a strategy to capture profits while maintaining an ultra long-view.

Looking ahead, I expect the stock market to do very well leading into the new year 2021.

drendo4u123Dec 7, 2020 5:22 PM

BCRX is looking good for another gap up tomorrow. The 325 mil funding to help launch the drug will ensure no dilution.

sideburnDec 7, 2020 7:50 PM

CLVS - Will re-enter if it slides more.

Biosci.capital.partnersLeaderModeratorDec 7, 2020 7:55 PM

sideburn Congrats on your buying and holding decision. CLVS is volatile indeed but I like its long term fundamentals and prospects. As for AXSM, it's a solid company, still trading far below its true worth.

sideburnDec 7, 2020 8:00 PM

AMRN - Good entry price here as it looks like it will continue to climb. New data presented at the NLA (COVID 19 info), then EMA, plus more developments in China next year.

Biosci.capital.partnersLeaderModeratorDec 7, 2020 8:01 PM

sideburn Exactly. The debacles are behind AMRN. Now, there's more catalyst with China and EMA to give the shares a sustained boost.

sideburnDec 7, 2020 8:03 PM

ITCI - Love this stock. Traded out after the nice surprise earnings run-up to $28. Bought back in at $23.90 recently. Will hold on to that until it shoots up again. One of these days it will stock, but it’s been great to swing.

Biosci.capital.partnersLeaderModeratorDec 7, 2020 8:04 PM

sideburn I like how you are long-term oriented. At the same time, you're opportunistic in catching the swing cycles. Great job! In my view, the best time to buy a mega growth stock is after a big pullback.

sideburnDec 7, 2020 8:07 PM

Yeah, I think AMRN is on the way back up. I think it’s shaken off the dust from its patent lawsuit in the US and has the momentum/buyers back to realize the market opportunity in Europe and China. May double from today’s price into Q2?

Biosci.capital.partnersLeaderModeratorDec 7, 2020 8:09 PM

sideburn how high do you see AMRN, CLVS, and ITCI will climb by yearend?

sideburnDec 7, 2020 8:36 PM

Based on today’s price, I’m most bullish on AMRN. Next would be ITCI because it’s safer than CLVS. Not sure if ITCI has any catalysts coming up, maybe the sNDA to expand the market for Caplyta comes out by EOY? CLVS is just so manipulated it’s hard to say. Will the IND for FAP-2286 help? Not sure if they just need to show stronger sales before they move up. Truth be told, it’s not in a bad buy area if you’re patient. Looks like there’s strong support at ~$4.10. Someone was loading up on shares down there. Triggering lots of stop losses. One of these days it’s going to fly. I don’t trust CLVS enough to hold it’s price so I’ll wait to see if it gravitates back into the $4’s again.

Biosci.capital.partnersLeaderModeratorDec 7, 2020 8:38 PM

sideburn You wrote a great summary on those 3 stocks. That's exactly what I'm thinking. With the patent issue behind AMRN, I see very good days ahead for that stock. As to ITCI, it will come down to improving sales for Caplyta. And the label expansion will boost the share price to a new height. As for CLVS, lots of volatility, but it's one of those wild cards that will move extremely fast when it times come.

That aside, I believe that AMRN can hit $7 by yearend. AMRN burned a lot of the big hitters so they don't want to touch it. And yet, that's the best time to buy. Eventually, the sentiment pendulum will swing from extreme pessimism to extreme optimism. Right now, it's still in extreme pessimism but it's heading the other direction toward positivity.

sideburnDec 7, 2020 8:42 PM

Myovant (MYOV) is another one that’s been red hot. Not sure if I will hold or sell immediately after it gets its PDUFA approval. It might not drop much afterward since most holders anticipate Sumi will buy it. But it’s hard to imagine Sumi is going to buy it close to where it will be trading at what will likely be an all-time high. I’ve heard they’ve played games before, so maybe this will end up like an AIMT situation? Not sure what to do about MYOV post (assumed) approval.

Biosci.capital.partnersLeaderModeratorDec 7, 2020 8:43 PM

I like AMRN b/c, despite the misfortune that came out of the blue for their patent issue, they have strong management. The Management as part of the M4 (Medicine, Market, Money, Management) is most crucial. And with a stellar management, they will right the ship.

sideburnDec 7, 2020 8:43 PM

Think it could easily touch $7.

Biosci.capital.partnersLeaderModeratorDec 7, 2020 8:45 PM

sideburn MYOV has moved from $15.42 to $23.53 in the past month. Super red hot. While buyout is definitely a possibility, I prefer organic growth. The interesting thing is that IBI covers only top stocks. So the big companies know where to look to find M&A targets.

Relu is a great medicine and I expect approval to come in due time.

I'm kinda upset that AIMT sold for such a low valuation. Maybe Nestle's was suppressing their shares. Maybe. I don't know.

sideburnDec 7, 2020 8:48 PM

I hope you’re right! I’ve been treating it like a done deal. Lots of folks here snatched MYOV up when it gapped down. I’m sure part of that had to do with your confidence in the company, molecule, and PDUFA prospects.

I think Nestle probably pulled some hanky panky.

Biosci.capital.partnersLeaderModeratorDec 7, 2020 8:50 PM

sideburn I'm highly confident about MYOV's drug. At IBI, we have many experts who seen countless market cycles. I saw great stocks rise and fell. And when I saw MYOV fell, I knew it was only temporary. After all, Relu is a stellar drug that was misunderstood by the market.

As you know, buying when the stock tumbled takes tremendous courage. You have to overcome your fear, which we at IBI knows that's it's nothing more than False Expectations Appearing Real. The credits go to you and IBI members for having the courage. I share the research and recommendation but you're the one who is wise to pull the metaphoric trigger. Cheers, my friend.

One of these days, we all should get together for some Scottish whiskey.

sideburnDec 7, 2020 8:54 PM

That would be excellent!

bilo.sellhiDec 8, 2020 12:34 AM

Biosci.capital.partners Dr Tran. Thank u for GBT article. I looked back and realized I first started following and investing in GBT after reading a June 2018 article u posted on the free site. Had my eye on u and GBT after that. Eventually joined IBI. Obviously no regrets. GBT and AIMT were the first, and among the most profitable, bio stocks I’ve owned. Best profits ahead with GBT. Have benefited greatly from your research and advice in articles and via the chat room. Also have benefited from insights and information from other IBI members in chat room. GTLA. Long GBT.

Biosci.capital.partnersLeaderModeratorDec 8, 2020 12:36 AM

bilo.sellhi Thank you, my friend. As I'm about to go to bed, I saw your message. And that made my day. Being in a supportive family of experts helped me learn tremendously over the years. In that time frame, I learned about many stocks from members as well as tidbits of wisdom. Have a good night.

Final Remarks

That's all for today. As alluded, I recently published an article on Global Blood Therapeutics (GBT) that you don't want to miss out on.

Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstance are individualized.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.